Prof. Ladislav Mirossay, M.D., D.Sc.

Last update: 23. 10. 2023

I. BASIC INFORMATION
I.1 Surname Mirossay
I.2 Name Ladislav
I.3 Titles Prof. , M.D., D.Sc.
I.4 Year of birth 1955
I.5 Name of the workplace University of Veterinary Medicine and Pharmacy in Košice, Pavol Jozef Šafárik University in Košice
I.6 Address of the workplace Komenského 73, 041 81 Košice, Slovak Republic
I.7 Position professor
I.8 E-mail address ladislav.mirossay@upjs.sk
I.9 Hyperlink to the entry of a person in the Register of university staff https://www.portalvs.sk/regzam/detail/14976
I.10 Name of the study field in which a person works at the university pharmacy
I.11 ORCID iD 3 https://orcid.org/0000-0002-7974-4525
3 Optional item.

II. HIGHER EDUCATION AND FURTHER QUALIFICATION GROWTH
II.a Name of the university or institution II.b Year II.c Study field and programme
II.1 First degree of higher education
II.2 Second degree of higher education Pavol Jozef Šafárik University in Košice, Faculty of Medicine 1979 stomatology
II.3 Third degree of higher education Pavol Jozef Šafárik University in Košice, Faculty of Medicine 1984 pharmacology
II.4 Associate professor Pavol Jozef Šafárik University in Košice, Faculty of Medicine 1994 pharmacology
II.5 Professor Charles University in Praque, 1. Faculty of Medicine 2003 medical pharmacology
II.6 Doctor of Science (DrSc.) Slovak Academy of Science in Bratislava 2001 pharmacology

III. CURRENT AND PREVIOUS EMPLOYMENT
III.a Occupation-position III.b Institution III.c Duration
professor Pavol Jozef Šafárik University, Faculty of Medicine 2003 up to now
associate professor Pavol Jozef Šafárik University, Faculty of Medicine 1994 2003
lecturer Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Institute of Pharmacology 1983 1994
doctoral student Pavol Jozef Šafárik University, Faculty of Medicine 1980 1983

IV. DEVELOPMENT OF PEDAGOGICAL, PROFESSIONAL, LANGUAGE, DIGITAL AND OTHER SKILLS
IV.a Activity description, course name, other IV.b Name of the institution IV.c Year
Summer course on problem-based pharmaco-therapy teaching Gröningen, Netherlands 1996
internship abroad INSERM, Hôpital St. Antoine, Paris 1993
internship abroad INSERM, Hôpital St. Antoine, Paris 1991
internship abroad Institute of Pharmcology, Hôpital Cochin/Port Royal, Paris 1988

V. OVERVIEW OF ACTIVITIES WITHIN THE TEACHING CAREER AT THE UNIVERSITY
V.1. Overview of the profile courses taught in the current academic year according to study programmes
V.1.a Name of the profile course V.1.b Study programme V.1.c Degree V.1.d Field of study
Pharmacologypharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy

V.2. Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year 4
V.2.a Study programme V.2.b Degree V.2.d Field of study
4 According to Art. 6 para. 4 of the Standards for the Study Programme.

V.3. Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.3.a Name of the field of habilitation procedure and inaugural procedure V.3.b Study field to which it is assigned

V.4. Overview of supervised final theses
V.4.a Bachelor's (first degree) V.4.b Diploma (second degree) V.4.c Dissertation (third degree)
V.4.1 Number of currently supervised theses 0 0 0
V.4.2 Number of defended theses 0 4 6

V.5. Overview of other courses taught in the current academic year according to study programmes
V.5.a Name of the course V.5.b Study programme V.5.c Degree V.5.d Field of study
Pharmacologypharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy

VI. OVERVIEW OF THE RESEARCH/ARTISTIC/OTHER OUTPUTS
VI.1. Overview of the research/artistic/other outputs and the corresponding citations
VI.1.a Overall VI.1.b Over the last six years
VI.1.1 Number of the research/artictic/other outputs 422 24
VI.1.2 Number of the research/artictic/other outputs registered in the Web of Science or Scopus databases 102 6
VI.1.3 Number of citations corresponding to the research/artictic/other outputs 1468 528
VI.1.4 Number of citations registered in the Web of Science or Scopus databases 1468 528
VI.1.5 Number of invited lectures at the international, national level 1 1

VI.2. The most significant research/artistic/other outputs 5
1. ADC: DIRENZO, M. F. - CHASTRE, Eric - GIACOMINI, A. - MIROSSAY, Ladislav - OLIVERO, M. - PORTE, H.[et al.13].: Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. In: Clinical Cancer Research. - Vol. 1, no. 2 (1995), s. 147-154. cit. 332 x
2. ADC: Mojzis J., Varinska L., Mojzisova G., Kostova I, Mirossay L.: antiangogenic effect of flavonoids and chalcones. Pharmacol. Res. 57, 259-265, 2008 (IF=3,929; Q1 - SJR) cit. 200 x
3. ADC: Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A.: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 10, 62-69, 2010. (IF=4,306; Q1) cit. 72 x
4. ADC: Mojžiš J., Varinská L., ADC: Pilatova M, Varinska L, Perjesi P, Sarissky M, Mirossay L, Solar P, Ostro A, Mojzis J.: In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicol In Vitro. 24, 1347-1355, 2010. (IF=2,959; Q1) cit. 47 x
5. ADC: Sabo, J., Mirossay, L., Horovcak, L., Sarissky, M., Mirossay, A., Mojzis, J.: Effects of static magnetic field on human leukemic cell line HL-60. Bioelectrochemistry 56, 227-231, 2002. (IF=1,46; Q1) cit. 75 x
5 Maximum of five most significant outputs, if the RATP form is attached to the application.

VI.3. The most significant research/artistic/other outputs over the last six years 6
1. ADC: Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J.: Soy and Breast Cancer: Focus on Angiogenesis. Int J Mol Sci. 16, 11728-11749, 2015 (IF= 3.257; Q1). Cit. 85 x.
2. ADC: Mirossay L, Varinská L, Mojžiš J. Antiangiogenic Effect of Flavonoids and Chalcones: An Update. Int J Mol Sci. 19, pii: E27., 2018 (IF=3,226; Q1) cit. 34 x
3. ADC: Mojžišová G., Kello M., Pilátová M., Tomečková V., Vašková J., Vaško L., Bernátová S., Mirossay L., Mojžiš J: Antiproliferative effect of ß-escin - an in vitro study. In: Acta Biochimica Polonica. - ISSN 0001-527X. - Vol. 63, no. 1 (2016), s. 79-87. 2016 (IF=1,153; Q2) cit. 16 x
4. ADC: Cizmarikova, M., Podracka, L., Klimcakova, L., Mojzis, J., Mirossay, L.: MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: Preliminary results. Medical Science Monitor 21, pp. 59-68 2015 (IF=1,126; Q2) cit. 15 x
5. ADC: Solárová, Z., Kello, M., Hamuľaková, S., Mirossay, L., Solár, P. Anti-cancer effect of tacrine-coumarin derivatives on diverse human and mouse cancer cell lines. Acta Chimica Slovenica 65(4), pp. 875-881 2018 (IF= 1,104; Q3) cit 2 x
6 Maximum of five most significant outputs over the last six years, if the RATP form is attached to the application.

VI.4. The most significant citations corresponding to the research/artistic/other outputs 7
1. Citovaný dokument: Mojzis J., Varinska L., Mojzisova G., Kostova I, Mirossay L.: antiangogenic effect of flavonoids and chalcones. Pharmacol. Res. 57, 259-265, 2008 (IF=3,929; Q1 - SJR) cit. 200 x Ohlas: ADC: Wang L, Jin Y, Arnoldussen YJ, , Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F.: STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer. Cancer Res 70, 5818-5828, 2010 (IF=9,13; Q1)
2. Citovaný dokument: Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A.: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 10, 62-69, 2010. (IF=4,306; Q1) cit. 72 x Ohlas: ADC: Kim HJ., Im SA., Keam B., Ham HS., Lee KH., Kim TY., Kim YJ., Oh DY., Kim JH., Han W., Park IA., Noh D.Y.: ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106, 86-93, 2015. (IF=4,966; Q1)
3. Citovaný dokument: Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J.: Soy and Breast Cancer: Focus on Angiogenesis. Int J Mol Sci. 16, 11728-11749, 2015 (IF= 3.257; Q1). cit. 85 x; Ohlas: ADC: Molina, Luis; Bustamante, Felipe A.; Bhoola, Kanti D.; et al. Possible role of phytoestrogens in breast cancer via GPER-1/GPR30 signaling. Clin Sci 132, 2583-2598, 2018 (IF=5,22; Q1)
4. Citovaný dokument: Mirossay L, Varinská L, Mojžiš J. Antiangiogenic Effect of Flavonoids and Chalcones: An Update. Int J Mol Sci. 19, pii: E27., 2018 (IF=3,226; Q1) cit. 31x; Ohlas: ADC: Dirimanov, Stoyan; Hoegger, Petra. Screening of Inhibitory Effects of Polyphenols on Akt-Phosphorylation in Endothelial Cells and Determination of Structure-Activity Features. Biomolecules 9, Article Number: 219, 2019 (IF=4,082; Q1)
5. Citovaný dokument: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit 36x; Ohlas: ADC: Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C.,(Muller, A. J.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851-2857, 2008 (IF=7.55; Q1)
7 Maximum of five most significant citations, if the RATP form is attached to the application.

VI.5. Participation in conducting (leading) the most important research projects or art projects over the last six years 8
1. PVV–0408–12: Galektíny a angiogenéza. Roky realizácie: 2013-2017: Pozícia:spoluriešiteľ
2. APVV-16-0446; Bunkové interakcie v nádorovom mikroprostredí a ich farmakologické ovplyvnenie. Roky realizácie: 2017-2021; spoluriešiteľ
3. VEGA 1/0753/17; Vplyv prírodných látok na nádorové mikroprostredie. Roky realizácie: 2017-2020, Pozícia: spoluriešiteľ
4. OPENMED: „Otvorená vedecká komunita pre moderný interdisciplinárny výskum v medicíne“, kód ITMS2014+: 313011V455; Pozícia: spoluriešiteľ aktivity 7.1
5. VEGA 1/0513/21; Klinická relevantnosť expresie PD receptorov „programovanej smrti“ v mikroprostredí karcinómov mliečnej žlazy. 2021-2024; PI
8 Maximum of five most significant projects, if the RATP form is attached to the application. In addition to the name and brief characteristics of the project, the type of participation is indicated (in Slovak and in English), if possible, a hyperlink to the project and its outputs and citations are stated as well.

VII. OVERVIEW OF ORGANIZATIONAL EXPERIENCE RELATED TO HIGHER EDUCATION AND RESEARCH/ARTISTIC/OTHER ACTIVITIES 9
VII.a Activity, position VII.b Name of the institution, board VII.c Duration
Member or chairman of Scientific Board of PJŠU FM PJŠU in Košice, Faculty of Medicine 2018 up to now
Chairman of the Defense DrSc. Pavol Jozef Šafárik University 2014 2021
Member or chairman of Scientific Board of PJŠU FM PJŠU in Košice, Faculty of Medicine 2007 2015
Head of the Institute of Pharmacology PJŠU in Košice, Faculty of Medicine, Institute of Pharmacology 2004 2007
Member of the Committee of the Slovak Pharmacological Society and member of the Slovak Oncological Society SLS 2000 up to now
1997 2015
Head of the Institute of Pharmacology PJŠU in Košice, Faculty of Medicine, Institute of Pharmacology 1995 1999
Member or chairman of Scientific Board of PJŠU FM PJŠU in Košice, Faculty of Medicine 1994 2003
9 E.g. academic positions, memberships in editorial boards and in scientific and professional societies.

VIII. OVERVIEW OF INTERNATIONAL MOBILITIES AND VISITS ORIENTED ON EDUCATION AND RESEARCH/ARTISTIC/ OTHER ACTIVITIES IN THE GIVEN FIELD OF STUDY
VIII.a Name of the institution VIII.b Address of the institution VIII.c Duration (indicate the duration of stay) VIII.d Mobility scheme, employment contract, other (describe)
Summer course on problem-based pharmaco-therapy teaching Gröningen, Netherlands 1996 1996 participant
INSERM U.55 Hôpital Cochin/Port Royal, Paris 1993 1993 trainee of the French Government
INSERM U.55 Hôpital St. Antoine, Paris 1990 1991 trainee of the French Government
Institute of Pharmcology Hôpital Cochin/Port Royal, Paris 1988 1989 trainee of the French Government

IX. OTHER RELEVANT FACTS 10
IX.a If relevant, other activities related to higher education or research/artictic/other activities are mentioned
1. 1994, 1995, 2005 - 1st author of works that were evaluated as the best publications - Faculty of Medicine UPJŠ 2. 1996, 1998 - co-author of works that were evaluated as the best publications - Faculty of Medicine UPJŠ 3. 1997 - 1st author of the pharmacology textbook, evaluated as the best monograph at the Faculty of Medicine UPJŠ 4. 1999 - co-author of the pharmacology textbook, evaluated as the best monograph at the Faculty of Medicine UPJŠ 5. 1999 - 1st author of the lecture, best evaluated by members of the Slovak and Czech Pharmacological Society within the framework of the 49th Pharmacological Days in Bratislava 6. 1997 - Honorary citizen of the City of Mobile, USA 7. 1998 - Commemorative letter and silver medal of the 3rd Faculty of Medicine of Charles University in Prague for cooperation between Czech and Slovak medical faculties 8. 2000 - Plaque of the Mayor of Košice for the development of international scientific research contacts in medicine 9. 2002 - Silver medal on the occasion of the 50th anniversary of the founding of the Faculty of Engineering at TU Košice 10. 2002 - Commemorative medal for cooperation in the development of JLF UK in Martin 11. 2003 - Commemorative medal for supporting the activities of the National Institute of Rheumatic Diseases in Piešťany on the occasion of the 50th anniversary of its foundation 12. 2004 - Silver plaque of the Trauma Surgery Clinic of the Faculty of Medicine UPJŠ and FNLP for help in the development of trauma surgery 13. 2004 - Medal of the University of Nantes for long-term cooperation on the occasion of the Erasmus-Socrates meeting 14. 2008 – Gold medal of the Faculty on the occasion of the 60th anniversary of the founding of the faculty 15. 2009 – Honorary member of the Slovak Pharmaceutic ...
10 Maximum of 1800 characters, if the RATP form is attached to the application.
Skip to content